29 results on '"Lim, Darren Wan-Teck"'
Search Results
2. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
3. Matrisomics: Beyond the extracellular matrix for unveiling tumor microenvironment
4. Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer
5. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
6. Efficacy of Anti-PD1 Blockade in Treating Recurrent or Metastatic Nasopharyngeal Cancer: A Systematic Review and Meta-analysis
7. International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic
8. Effect of tumor-immune microenvironment (TIME) on disparate ascending (A) and descending (D) subtypes of nasopharyngeal carcinoma (NPC).
9. Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
10. CYP2A6 Genetic Polymorphism and Nicotine Metabolism of Male Smokers in Indonesia.
11. High-Throughput Microfluidic Extraction of Platelet-free Plasma for MicroRNA and Extracellular Vesicle Analysis.
12. Is There a Unicorn Among the Uncommon EGFR Mutations?
13. Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC.
14. Immunotherapy with chemotherapy and anti-angiogenic therapy for EGFR mutated NSCLC: challenging the dogma.
15. Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.
16. Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment.
17. Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC).
18. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.
19. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
20. Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC.
21. NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).
22. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
23. Érythème au site d'une cicatrice du vaccin bacille de Calmette–Guérin après l'obtention d'une dose du vaccin à ARN messager contre le SRAS-CoV-2.
24. Bacillus Calmette-Guérin scar flare after an mRNA SARS-CoV-2 vaccine.
25. Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
26. Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy.
27. MULTIPLEXED MUTATION PROFILING OF ASIAN LUNG ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA REVEALS THERAPEUTICALLY RELEVANT ALTERATIONS.
28. Response to fam-Trastuzumab-Deruxtecan in patients with metastatic HER2-positive salivary duct carcinoma: A case series.
29. MO2-6-3 Matrisomal abnormality: a predictive biomarker for cancer immunotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.